The phase 3 IMforte study randomised adults with extensive-stage SCLC to receive Roche’s PD-L1 inhibitor Tecentriq ...

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is making headlines after its Phase 3 ROSELLA trial showed relacorilant, ...

Telix Pharmaceuticals (ASX:TLX) recently gained marketing authorization for its prostate cancer imaging agent, Illuccix®, in Portugal. This development enhances diagnostic options in a country where ...

Every day, manufacturers continue to develop new, life-saving cancer treatments ... as large pharmaceutical manufacturers while adding the advantages of scalability, speed, and risk sharing.

Officially completing its acquisition of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT), Sun Pharmaceutical Industries Ltd. has ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102.

Mumbai: Sun Pharmaceutical Industries Limited has announced the successful completion of its acquisition of Checkpoint ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

Astellas Pharma (ALPMY) and Pfizer (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ...

The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death.